Bembenek SD - Search Results

1

Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling.

Bembenek SD, Keith JM, Letavic MA, Apodaca R, Barbier AJ, Dvorak L, Aluisio L, Miller KL, Lovenberg TW, Carruthers NI. Bembenek SD, et al. Bioorg Med Chem. 2008 Mar 15;16(6):2968-73. doi: 10.1016/j.bmc.2007.12.048. Epub 2007 Dec 25. Bioorg Med Chem. 2008. PMID: 18249544

2

Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.

Axe FU, Bembenek SD, Szalma S. Axe FU, et al. Among authors: bembenek sd. J Mol Graph Model. 2006 May;24(6):456-64. doi: 10.1016/j.jmgm.2005.10.005. Epub 2005 Dec 28. J Mol Graph Model. 2006. PMID: 16386444

3

The role of molecular size in ligand efficiency.

Reynolds CH, Bembenek SD, Tounge BA. Reynolds CH, et al. Among authors: bembenek sd. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4258-61. doi: 10.1016/j.bmcl.2007.05.038. Epub 2007 May 17. Bioorg Med Chem Lett. 2007. PMID: 17532632

4

Ligand binding efficiency: trends, physical basis, and implications.

Reynolds CH, Tounge BA, Bembenek SD. Reynolds CH, et al. Among authors: bembenek sd. J Med Chem. 2008 Apr 24;51(8):2432-8. doi: 10.1021/jm701255b. Epub 2008 Apr 2. J Med Chem. 2008. PMID: 18380424

5

Dual binding site inhibitors of B-RAF kinase.

Wolin RL, Bembenek SD, Wei J, Crawford S, Lundeen K, Brunmark A, Karlsson L, Edwards JP, Blevitt JM. Wolin RL, et al. Among authors: bembenek sd. Bioorg Med Chem Lett. 2008 May 1;18(9):2825-9. doi: 10.1016/j.bmcl.2008.04.002. Epub 2008 Apr 4. Bioorg Med Chem Lett. 2008. PMID: 18434146

6

Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.

Grice CA, Tays KL, Savall BM, Wei J, Butler CR, Axe FU, Bembenek SD, Fourie AM, Dunford PJ, Lundeen K, Coles F, Xue X, Riley JP, Williams KN, Karlsson L, Edwards JP. Grice CA, et al. Among authors: bembenek sd. J Med Chem. 2008 Jul 24;51(14):4150-69. doi: 10.1021/jm701575k. Epub 2008 Jun 28. J Med Chem. 2008. PMID: 18588282

7

Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements.

Ameriks MK, Axe FU, Bembenek SD, Edwards JP, Gu Y, Karlsson L, Randal M, Sun S, Thurmond RL, Zhu J. Ameriks MK, et al. Among authors: bembenek sd. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6131-4. doi: 10.1016/j.bmcl.2009.09.014. Epub 2009 Sep 10. Bioorg Med Chem Lett. 2009. PMID: 19773165

8

Thioether acetamides as P3 binding elements for tetrahydropyrido-pyrazole cathepsin S inhibitors.

Wiener DK, Lee-Dutra A, Bembenek S, Nguyen S, Thurmond RL, Sun S, Karlsson L, Grice CA, Jones TK, Edwards JP. Wiener DK, et al. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2379-82. doi: 10.1016/j.bmcl.2010.01.103. Epub 2010 Feb 8. Bioorg Med Chem Lett. 2010. PMID: 20188543

9

Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors.

Ameriks MK, Bembenek SD, Burdett MT, Choong IC, Edwards JP, Gebauer D, Gu Y, Karlsson L, Purkey HE, Staker BL, Sun S, Thurmond RL, Zhu J. Ameriks MK, et al. Among authors: bembenek sd. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4060-4. doi: 10.1016/j.bmcl.2010.05.086. Epub 2010 May 25. Bioorg Med Chem Lett. 2010. PMID: 20541404

10

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.

Jia H, Dai G, Su W, Xiao K, Weng J, Zhang Z, Wang Q, Yuan T, Shi F, Zhang Z, Chen W, Sai Y, Wang J, Li X, Cai Y, Yu J, Ren P, Venable J, Rao T, Edwards JP, Bembenek SD. Jia H, et al. Among authors: bembenek sd. J Med Chem. 2019 May 23;62(10):4936-4948. doi: 10.1021/acs.jmedchem.8b02014. Epub 2019 May 8. J Med Chem. 2019. PMID: 31033293

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters